Medicines for Malaria Venture (MMV)
@mmv.org
A leading global health partnership working to reduce the burden of malaria. We discover, develop and deliver new antimalarial medicines.
How do #malaria parasites survive in the mosquito gut?
Researchers have profiled gene activity to find out, revealing insights that could inform new transmission-blocking tools.
Read more in @nature.com: bit.ly/3XeaP4B
Researchers have profiled gene activity to find out, revealing insights that could inform new transmission-blocking tools.
Read more in @nature.com: bit.ly/3XeaP4B
November 28, 2025 at 3:27 PM
How do #malaria parasites survive in the mosquito gut?
Researchers have profiled gene activity to find out, revealing insights that could inform new transmission-blocking tools.
Read more in @nature.com: bit.ly/3XeaP4B
Researchers have profiled gene activity to find out, revealing insights that could inform new transmission-blocking tools.
Read more in @nature.com: bit.ly/3XeaP4B
Press release 📢 Announcing MMV's new partnership with South Korean biotechnology leader Shaperon to advance game-changing, nanobody treatments for #malaria prevention.
🎥 Watch the video to learn how nanobody technology can change the game for #GlobalHealth.
🎥 Watch the video to learn how nanobody technology can change the game for #GlobalHealth.
November 27, 2025 at 1:08 PM
Press release 📢 Announcing MMV's new partnership with South Korean biotechnology leader Shaperon to advance game-changing, nanobody treatments for #malaria prevention.
🎥 Watch the video to learn how nanobody technology can change the game for #GlobalHealth.
🎥 Watch the video to learn how nanobody technology can change the game for #GlobalHealth.
Vivax #malaria relapses keep patients trapped in a cycle. The Partnership for Vivax Elimination (PAVE) has been generating evidence from across endemic countries to support country elimination goals.
November 27, 2025 at 11:27 AM
Vivax #malaria relapses keep patients trapped in a cycle. The Partnership for Vivax Elimination (PAVE) has been generating evidence from across endemic countries to support country elimination goals.
Is #malaria eradication still within reach?
Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment.
🎥 Watch it here: bit.ly/4inePJY
Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment.
🎥 Watch it here: bit.ly/4inePJY
November 26, 2025 at 12:53 PM
Is #malaria eradication still within reach?
Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment.
🎥 Watch it here: bit.ly/4inePJY
Experts at #ASTMH25, convened by @gatesfoundation.bsky.social & MMV for a sponsored symposium, say yes...with next-gen tools, strong endemic-country leadership & sustained investment.
🎥 Watch it here: bit.ly/4inePJY
Paul Boateng (Ghana NMEP) on staying ahead of antimalarial drug resistance, including the use of MFT to reduce pressure on ACTs. Through the ALARM partnership, MMV & Ghana's NMEP are conducting an MFT pilot following similar successful pilots in Kenya & Burkina Faso. #WAAW25
November 24, 2025 at 9:36 PM
Paul Boateng (Ghana NMEP) on staying ahead of antimalarial drug resistance, including the use of MFT to reduce pressure on ACTs. Through the ALARM partnership, MMV & Ghana's NMEP are conducting an MFT pilot following similar successful pilots in Kenya & Burkina Faso. #WAAW25
At #CPHIA2025, Dr Edwin Onyango from Kenya’s NMCP explained partial-artemisinin resistance.
MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.
#WAAW25
MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.
#WAAW25
November 24, 2025 at 4:21 PM
At #CPHIA2025, Dr Edwin Onyango from Kenya’s NMCP explained partial-artemisinin resistance.
MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.
#WAAW25
MMV & partners are developing a triple ACT, combining artemether-lumefantrine with amodiaquine. This medicine is now in Phase 3 clinical trials.
#WAAW25
Parasites developing resistance to #malaria mediciness isn’t a question of if, but when. We must act now to protect gains & secure a malaria-free future.
MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x
#WAAW25
MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x
#WAAW25
November 21, 2025 at 7:04 PM
Parasites developing resistance to #malaria mediciness isn’t a question of if, but when. We must act now to protect gains & secure a malaria-free future.
MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x
#WAAW25
MMV & partners are staying one step ahead of resistance 👉 bit.ly/47MmP3x
#WAAW25
For the first time in 25 years, a new class of #malaria treatment is within reach. Today, @Novartis & MMV announce positive Phase 3 results for a novel, non-artemisinin medicine with the potential to kill drug-resistant parasites & block transmission. bit.ly/4p78R1P
November 13, 2025 at 7:26 AM
For the first time in 25 years, a new class of #malaria treatment is within reach. Today, @Novartis & MMV announce positive Phase 3 results for a novel, non-artemisinin medicine with the potential to kill drug-resistant parasites & block transmission. bit.ly/4p78R1P
This week at #ASTMH25, the Partnership for Vivax Elimination (PAVE) network came together to show what’s possible when evidence, partnerships and policy align to turn innovative tools and collaborative research into real-world impact.
November 12, 2025 at 10:16 PM
This week at #ASTMH25, the Partnership for Vivax Elimination (PAVE) network came together to show what’s possible when evidence, partnerships and policy align to turn innovative tools and collaborative research into real-world impact.
We are the impatient optimists who believe in #malaria eradication in our lifetime. Today at #ASTMH25, MMV & @gatesfoundation.bsky.social convened leading global health experts for a special symposium to reaffirm their shared belief in a malaria-free future. Stay tuned for the video.
November 12, 2025 at 6:23 PM
We are the impatient optimists who believe in #malaria eradication in our lifetime. Today at #ASTMH25, MMV & @gatesfoundation.bsky.social convened leading global health experts for a special symposium to reaffirm their shared belief in a malaria-free future. Stay tuned for the video.
MMV is at #ASTMH25!
Meet us in the exhibition hall at booth (512) – come for the Swiss chocolate and Italian coffee, stay for chats about our work & partnerships advancing the #malaria elimination agenda.
See all our activities at #TropMed25 this week 👉bit.ly/4hSZTmC
Meet us in the exhibition hall at booth (512) – come for the Swiss chocolate and Italian coffee, stay for chats about our work & partnerships advancing the #malaria elimination agenda.
See all our activities at #TropMed25 this week 👉bit.ly/4hSZTmC
November 10, 2025 at 5:13 PM
MMV is at #ASTMH25!
Meet us in the exhibition hall at booth (512) – come for the Swiss chocolate and Italian coffee, stay for chats about our work & partnerships advancing the #malaria elimination agenda.
See all our activities at #TropMed25 this week 👉bit.ly/4hSZTmC
Meet us in the exhibition hall at booth (512) – come for the Swiss chocolate and Italian coffee, stay for chats about our work & partnerships advancing the #malaria elimination agenda.
See all our activities at #TropMed25 this week 👉bit.ly/4hSZTmC
Heading to #ASTMH2025 in Toronto? 🇨🇦
MMV will be on hand in the exhibition hall (booth 512) & throughout the week, sharing research via scientific symposia & poster/oral presentation sessions. Explore MMV & partner activities at the ASTMH Annual Meeting: bit.ly/4hSZTmC
MMV will be on hand in the exhibition hall (booth 512) & throughout the week, sharing research via scientific symposia & poster/oral presentation sessions. Explore MMV & partner activities at the ASTMH Annual Meeting: bit.ly/4hSZTmC
November 7, 2025 at 10:40 AM
Heading to #ASTMH2025 in Toronto? 🇨🇦
MMV will be on hand in the exhibition hall (booth 512) & throughout the week, sharing research via scientific symposia & poster/oral presentation sessions. Explore MMV & partner activities at the ASTMH Annual Meeting: bit.ly/4hSZTmC
MMV will be on hand in the exhibition hall (booth 512) & throughout the week, sharing research via scientific symposia & poster/oral presentation sessions. Explore MMV & partner activities at the ASTMH Annual Meeting: bit.ly/4hSZTmC
MMV staff are celebrating #MalariaDayInTheAmericas by joining the Brazilian #MedTrop25 Conference in Belém this week!
November 6, 2025 at 8:06 PM
MMV staff are celebrating #MalariaDayInTheAmericas by joining the Brazilian #MedTrop25 Conference in Belém this week!
Symposium: MMV & partners at #ASTMH2025
📅 10 Nov: Evidence to guide the implementation of effective P. vivax radical cure
Lessons from Brazil, Peru, PNG & Indonesia on optimizing radical cure for vivax #malaria relapse prevention
Speakers & topics 👉 bit.ly/3KVqVx7
📅 10 Nov: Evidence to guide the implementation of effective P. vivax radical cure
Lessons from Brazil, Peru, PNG & Indonesia on optimizing radical cure for vivax #malaria relapse prevention
Speakers & topics 👉 bit.ly/3KVqVx7
November 3, 2025 at 6:08 PM
Symposium: MMV & partners at #ASTMH2025
📅 10 Nov: Evidence to guide the implementation of effective P. vivax radical cure
Lessons from Brazil, Peru, PNG & Indonesia on optimizing radical cure for vivax #malaria relapse prevention
Speakers & topics 👉 bit.ly/3KVqVx7
📅 10 Nov: Evidence to guide the implementation of effective P. vivax radical cure
Lessons from Brazil, Peru, PNG & Indonesia on optimizing radical cure for vivax #malaria relapse prevention
Speakers & topics 👉 bit.ly/3KVqVx7
MMV & Chiang Mai University have launched a qualitative study in Thailand on paediatric formulations of primaquine and tafenoquine for P. vivax #malaria relapse prevention, exploring perceptions around their use with G6PD testing.
October 30, 2025 at 11:12 AM
MMV & Chiang Mai University have launched a qualitative study in Thailand on paediatric formulations of primaquine and tafenoquine for P. vivax #malaria relapse prevention, exploring perceptions around their use with G6PD testing.
Malaria can become deadly within hours. Through SEMA ReACT, MMV & partners are studying rectal artesunate use in remote Zambia & DRC to improve severe #malaria care. Join us at #ASTMH2025 (11 Nov) for a symposium sharing interim results & insights 👉 bit.ly/46Z7ADQ
October 29, 2025 at 3:37 PM
Malaria can become deadly within hours. Through SEMA ReACT, MMV & partners are studying rectal artesunate use in remote Zambia & DRC to improve severe #malaria care. Join us at #ASTMH2025 (11 Nov) for a symposium sharing interim results & insights 👉 bit.ly/46Z7ADQ
Diversifying the use of #malaria meds through the deployment of MFT can keep us one step ahead of resistance. MMV & partners recently conducted a feasibility study in Kenya demonstrating that an MFT approach is feasible, with adequate resources 👉 bit.ly/3IVeQYh
October 29, 2025 at 1:54 PM
Diversifying the use of #malaria meds through the deployment of MFT can keep us one step ahead of resistance. MMV & partners recently conducted a feasibility study in Kenya demonstrating that an MFT approach is feasible, with adequate resources 👉 bit.ly/3IVeQYh
Are you subscribed to MMV’s monthly newsletter?
Get the latest news on MMV projects, partnerships & initiatives advancing the global #malaria elimination agenda, as well as info on events, scientific publications & job opportunities within MMV
👉 bit.ly/MMVnewsletter
Get the latest news on MMV projects, partnerships & initiatives advancing the global #malaria elimination agenda, as well as info on events, scientific publications & job opportunities within MMV
👉 bit.ly/MMVnewsletter
October 28, 2025 at 8:36 AM
Are you subscribed to MMV’s monthly newsletter?
Get the latest news on MMV projects, partnerships & initiatives advancing the global #malaria elimination agenda, as well as info on events, scientific publications & job opportunities within MMV
👉 bit.ly/MMVnewsletter
Get the latest news on MMV projects, partnerships & initiatives advancing the global #malaria elimination agenda, as well as info on events, scientific publications & job opportunities within MMV
👉 bit.ly/MMVnewsletter
“Innovation can’t wait; we need to act now,” says MMV CEO Martin Fitchet, in an opinion piece on the urgent need to stop #malaria drug resistance in its tracks. Read it in @devex.com
👉 bit.ly/42UQ8xU
👉 bit.ly/42UQ8xU
October 23, 2025 at 8:00 AM
“Innovation can’t wait; we need to act now,” says MMV CEO Martin Fitchet, in an opinion piece on the urgent need to stop #malaria drug resistance in its tracks. Read it in @devex.com
👉 bit.ly/42UQ8xU
👉 bit.ly/42UQ8xU
A #malaria resurgence would cost lives and crush economies.
A new report warns that without full funding for The Global Fund’s 8th Replenishment, the world risks losing hard-won progress in the fight against malaria.
Read it here 👉 bit.ly/48IJ637
A new report warns that without full funding for The Global Fund’s 8th Replenishment, the world risks losing hard-won progress in the fight against malaria.
Read it here 👉 bit.ly/48IJ637
October 21, 2025 at 10:27 AM
A #malaria resurgence would cost lives and crush economies.
A new report warns that without full funding for The Global Fund’s 8th Replenishment, the world risks losing hard-won progress in the fight against malaria.
Read it here 👉 bit.ly/48IJ637
A new report warns that without full funding for The Global Fund’s 8th Replenishment, the world risks losing hard-won progress in the fight against malaria.
Read it here 👉 bit.ly/48IJ637
Growing research infrastructure, stronger regulatory frameworks & new opportunities for collaboration are shifting Africa’s clinical trial landscape. 👉 See how harnessing Africa’s untapped clinical trial potential can benefit patients & business: bit.ly/4qema1Z
October 20, 2025 at 1:35 PM
Growing research infrastructure, stronger regulatory frameworks & new opportunities for collaboration are shifting Africa’s clinical trial landscape. 👉 See how harnessing Africa’s untapped clinical trial potential can benefit patients & business: bit.ly/4qema1Z
One country’s victory over #malaria can light the way for others. Suriname's path to elimination was forged by combining community engagement, rapid testing & effective treatment – an approach that can inspire strategies in other countries 👉 bit.ly/4q4jK5R
October 17, 2025 at 10:23 AM
One country’s victory over #malaria can light the way for others. Suriname's path to elimination was forged by combining community engagement, rapid testing & effective treatment – an approach that can inspire strategies in other countries 👉 bit.ly/4q4jK5R
Are we focusing on the most critical levers to end #malaria? Join MMV & @gatesfoundation.bsky.social at #ASTMH2025 to explore how breakthrough tools, smart strategies and endemic country leadership can help end malaria in our lifetime.
📅 Nov 12, 7:00am bit.ly/4356K60
📅 Nov 12, 7:00am bit.ly/4356K60
October 15, 2025 at 10:12 AM
Are we focusing on the most critical levers to end #malaria? Join MMV & @gatesfoundation.bsky.social at #ASTMH2025 to explore how breakthrough tools, smart strategies and endemic country leadership can help end malaria in our lifetime.
📅 Nov 12, 7:00am bit.ly/4356K60
📅 Nov 12, 7:00am bit.ly/4356K60
